uniQure (NASDAQ:QURE – Get Rating) reached a new 52-week low during mid-day trading on Wednesday after an insider sold shares in the company. The company traded as low as $11.56 and last traded at $11.87, with a volume of 2285649 shares traded. The stock had previously closed at $19.44.
Specifically, CFO Christian Klemt sold 1,587 shares of uniQure stock in a transaction dated Friday, June 16th. The stock was sold at an average price of $18.94, for a total value of $30,057.78. Following the completion of the sale, the chief financial officer now directly owns 132,854 shares in the company, valued at $2,516,254.76. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, CFO Christian Klemt sold 1,587 shares of uniQure stock in a transaction dated Friday, June 16th. The stock was sold at an average price of $18.94, for a total value of $30,057.78. Following the completion of the sale, the chief financial officer now directly owns 132,854 shares in the company, valued at $2,516,254.76. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Pierre Caloz sold 2,920 shares of the business’s stock in a transaction dated Friday, June 16th. The stock was sold at an average price of $18.80, for a total value of $54,896.00. Following the transaction, the chief operating officer now owns 110,215 shares of the company’s stock, valued at $2,072,042. The disclosure for this sale can be found here. Insiders sold a total of 6,808 shares of company stock worth $128,121 over the last three months. 3.73% of the stock is currently owned by company insiders.
Wall Street Analysts Forecast Growth
QURE has been the subject of several analyst reports. UBS Group decreased their target price on uniQure from $45.00 to $42.00 in a research report on Friday, May 19th. StockNews.com initiated coverage on uniQure in a research report on Thursday, May 18th. They set a “hold” rating for the company. Truist Financial decreased their target price on uniQure from $65.00 to $55.00 in a research report on Thursday, May 11th. HC Wainwright restated a “buy” rating and set a $90.00 target price on shares of uniQure in a research report on Tuesday, March 7th. Finally, Credit Suisse Group boosted their price objective on uniQure from $51.00 to $55.00 and gave the company an “outperform” rating in a research report on Tuesday, February 28th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, uniQure has a consensus rating of “Moderate Buy” and an average price target of $54.00.
uniQure Price Performance
uniQure (NASDAQ:QURE – Get Rating) last released its earnings results on Tuesday, May 9th. The biotechnology company reported ($1.63) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.61). The firm had revenue of $5.33 million during the quarter, compared to the consensus estimate of $26.20 million. uniQure had a negative net margin of 143.01% and a negative return on equity of 35.03%. As a group, research analysts anticipate that uniQure will post -2.51 EPS for the current fiscal year.
Institutional Investors Weigh In On uniQure
Several institutional investors have recently bought and sold shares of the company. Arizona State Retirement System raised its stake in shares of uniQure by 4.0% during the 4th quarter. Arizona State Retirement System now owns 11,867 shares of the biotechnology company’s stock worth $269,000 after purchasing an additional 458 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its holdings in shares of uniQure by 6.6% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 12,749 shares of the biotechnology company’s stock worth $257,000 after acquiring an additional 792 shares during the last quarter. Exchange Traded Concepts LLC increased its holdings in shares of uniQure by 3.4% during the 4th quarter. Exchange Traded Concepts LLC now owns 30,481 shares of the biotechnology company’s stock worth $691,000 after acquiring an additional 1,016 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of uniQure by 152.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,038 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 1,231 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of uniQure by 12.0% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,042 shares of the biotechnology company’s stock worth $273,000 after acquiring an additional 1,290 shares during the last quarter. Institutional investors own 86.29% of the company’s stock.
About uniQure
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease.
Read More
- Get a free research report on uniQure from StockNews.com
- Smartsheet Investors’ Hasty Exit Can Be Your Gain
- Agilent Technologies Stock: Ready to Rise off the Floor
- Oilfield Services Growing Faster Than Wider Energy Sector
- La-Z-Boy Reclines To The Buy Zone As Industry Normalizes
- Five stocks we like better than uniQure
Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.
